Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution

Molecular Oncology

Volumn 3, Issue 3, 2009, Pages 214-219

  Zhou, Wenjing ^a   Muggerud, Aslaug A ^b,c   Vu, Phuong ^b   Due, Eldri U ^b   Sørlie, Therese ^b,d   Børresen Dale, Anne Lise ^b,c   Wärnberg, Fredrik ^a   Langerød, Anita ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Breast cancer; DCIS; TP53 mutation

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GROWTH; CANCER INVASION; CLONE; FEMALE; GENE; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SOMATIC MUTATION; TP53 GENE;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OPEN READING FRAMES; POINT MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67349118370     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2009.03.001     Document Type: Article

References (27)

1. Aas T., Borresen A.L., Geisler S., Smith-Sorensen B., Johnsen H., Varhaug J.E., Akslen L.A., and Lonning P.E. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 2 7 (1996) 811-814
2. Allred D.C., Mohsin S.K., and Fuqua S.A. Histological and biological evolution of human premalignant breast disease. Endocr. Relat. Cancer 8 1 (2001) 47-61
3. Borresen-Dale A.L. TP53 and breast cancer. Hum. Mutat. 21 3 (2003) 292-300
4. Borresen A.L., Andersen T.I., Eyfjord J.E., Cornelis R.S., Thorlacius S., Borg A., Johansson U., Theillet C., Scherneck S., Hartman S., et al. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 14 1 (1995) 71-75
5. Claus E.B., Stowe M., and Carter D. Breast carcinoma in situ: risk factors and screening patterns. J. Natl. Cancer Inst. 93 23 (2001) 1811-1817
6. D'Assoro A.B., Busby R., Acu I.D., Quatraro C., Reinholz M.M., Farrugia D.J., Schroeder M.A., Allen C., Stivala F., Galanis E., et al. Impaired p53 function leads to centrosome amplification, acquired ERalpha phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts. Oncogene (2008)
7. Done S.J., Arneson C.R., Ozcelik H., Redston M., and Andrulis I.L. P53 protein accumulation in non-invasive lesions surrounding p53 mutation positive invasive breast cancers. Breast Cancer Res. Treat. 65 2 (2001) 111-118
8. Done S.J., Eskandarian S., Bull S., Redston M., and Andrulis I.L. p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. J. Natl. Cancer Inst. 93 9 (2001) 700-704
9. Elston E.W., and Ellis I.O. Method for grading breast cancer. J. Clin. Pathol. 46 2 (1993) 189-190
10. Hainaut P., and Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77 (2000) 81-137
11. Ho G.H., Calvano J.E., Bisogna M., Borgen P.I., Rosen P.P., Tan L.K., and Van Zee K.J. In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology. Cancer 89 11 (2000) 2153-2160
12. Holland R., Peterse J.L., Millis R.R., Eusebi V., Faverly D., van de Vijver M.J., and Zafrani B. Ductal carcinoma in situ: a proposal for a new classification. Semin. Diagn. Pathol. 11 3 (1994) 167-180
13. Hwang E.S., DeVries S., Chew K.L., Moore II D.H., Kerlikowske K., Thor A., Ljung B.M., and Waldman F.M. Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin. Cancer Res. 10 15 (2004) 5160-5167
14. Kang J.H., Kim S.J., Noh D.Y., Choe K.J., Lee E.S., and Kang H.S. The timing and characterization of p53 mutations in progression from atypical ductal hyperplasia to invasive lesions in the breast cancer. J. Mol. Med. 79 11 (2001) 648-655
15. Ko L.J., and Prives C. p53: puzzle and paradigm. Genes Dev. 10 9 (1996) 1054-1072
16. Levine A.J., Momand J., and Finlay C.A. The p53 tumour suppressor gene. Nature 351 6326 (1991) 453-456
17. Ma X.J., Salunga R., Tuggle J.T., Gaudet J., Enright E., McQuary P., Payette T., Pistone M., Stecker K., Zhang B.M., et al. Gene expression profiles of human breast cancer progression. Proc. Natl. Acad. Sci. U.S.A. 100 10 (2003) 5974-5979
18. Medina D., Kittrell F.S., Shepard A., Contreras A., Rosen J.M., and Lydon J. Hormone dependence in premalignant mammary progression. Cancer Res. 63 5 (2003) 1067-1072
19. Olivier M., Langerod A., Carrieri P., Bergh J., Klaar S., Eyfjord J., Theillet C., Rodriguez C., Lidereau R., Bieche I., et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin. Cancer Res. 12 4 (2006) 1157-1167
20. Oren M. Regulation of the p53 tumor suppressor protein. J. Biol. Chem. 274 51 (1999) 36031-36034
21. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., and Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 28 6 (2007) 622-629
22. Polyak K. Is breast tumor progression really linear?. Clin. Cancer Res. 14 2 (2008) 339-341
23. Powell B., Soong R., Iacopetta B., Seshadri R., and Smith D.R. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin. Cancer Res. 6 2 (2000) 443-451
24. Simpson J.F., Page D.L., and Edgerton M.E. p53 in Mammary ductal carcinoma in situ, mutations in high-grade lesions only?. J. Natl. Cancer Inst. 93 9 (2001) 666-667
25. Sjogren S., Inganas M., Norberg T., Lindgren A., Nordgren H., Holmberg L., and Bergh J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst. 88 3-4 (1996) 173-182
26. Vousden K.H. p53: death star. Cell 103 5 (2000) 691-694
27. Vousden K.H., and Lane D.P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8 4 (2007) 275-283